Skip to Main content Skip to Navigation
Journal articles

Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features

Romain Mathieu 1 Géraldine Pignot 2 Alexandre Ingles 2 Maxime Crépel 1 Pierre Bigot 3 Jean-Christophe Bernhard 4 Florence Joly 5, 6 Laurent Guy Alain Ravaud Abdel Rahmene Azzouzi Gwenaëlle Gravis 7 Christine Chevreau 8 Laurent Zini 9 Hervé Lang 10 Christian Pfister 11 Eric Lechevallier Pierre-Olivier Fais Julien Berger Bertrand Vayleux Morgan Rouprêt 12 François Audenet Aurélien Descazeaud 13 Jérôme Rigaud 14 Jean-Pascal Machiels Michael Staehler Laurent Salomon 15, 16 Jean-Marie Ferrière 4 François Kleinclauss 17, 18 Karim Bensalah 19, 20 Jean-Jacques Patard 21
1 Service d'urologie
2 Hôpital Bicêtre
3 Service d'urologie
4 Service d'urologie, andrologie et transplantation rénale
5 Cancers et préventions
6 UNICANCER/CRLC - Centre Régional de Lutte contre le Cancer François Baclesse [Caen]
7 Institut Paoli-Calmettes
8 Institut Claudius Regaud
9 Service d'urologie
10 Service Urologie
11 Service d'urologie [Rouen]
12 Service d'urologie et transplantation rénales [CHU Pitié-Salpétrière]
13 Service de Néphrologie, Dialyse, Transplantations [CHU Limoges]
14 Service d'urologie
15 Service d'urologie [Mondor]
16 IMRB - Institut Mondor de Recherche Biomédicale
17 RIGHT - Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098)
18 Service d'urologie, andrologie et transplantation rénale
19 CHU Pontchaillou [Rennes]
20 LTSI - Laboratoire Traitement du Signal et de l'Image
21 AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre)
Abstract : Objectives : The role of cytoreductive nephrectomy (CN) in the treatment of patients harboring metastatic renal cell carcinoma (mRCC) has become controversial since the emergence of effective targeted therapies. The aim of our study was to compare the overall survival (OS) between CN and non-CN groups of patients presenting with mRCC in the era of targeted drugs and to assess these outcomes among the different Memorial Sloan-Kettering Cancer Center (MSKCC) and The Eastern Cooperative Oncology Group (ECOG) performance status subgroups. Methods and materials A total of 351 patients with mRCC at diagnosis recruited from 18 tertiary care centers who had been treated with systemic treatment were included in this retrospective study. OS was assessed by the Kaplan-Meier method according to the completion of a CN. The population was subsequently stratified according to MSKCC and ECOG prognostic groups. Results Median OS in the entire cohort was 37.1 months. Median OS was significantly improved for patients who underwent CN (16.4 vs. 38.1 months, P<0.001). However, subgroup analysis demonstrated that OS improvement after CN was only significant among the patients with an ECOG score of 0 to 1 (16.7 vs. 43.3 months, P = 0.03) and the group of patients with good and intermediate MSKCC score (16.8 vs. 42.4 months, P = 0.02). On the contrary, this benefit was not significant for the patients with an ECOG score of 2 to 3 (8.0 vs. 12.6 months, P = 0.8) or the group with poor MSKCC score (5.2 vs. 5.2, P = 0.9). Conclusions CN improves OS in patients with mRCC. However, this effect does not seem to be significant for the patients in ECOG performance status groups of 2 to 3 or poor MSKCC prognostic group
Keywords : Survival Carcinoma Nephrectomy Renal cell
Document type :
Journal articles
Complete list of metadatas
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01260654
Contributor : Laurent Jonchère <>
Submitted on : Friday, January 22, 2016 - 2:39:30 PM
Last modification on : Thursday, January 21, 2021 - 2:10:03 PM

Identifiers

Collections

LTSI | UNIV-RENNES1 | UNIV-FCOMTE | UNIV-ANGERS | UMR645 | IMRB | UPEC-UPEM | COMUE-NORMANDIE | UNIV-RENNES | UNICAEN | UNIROUEN | U1086 | UNAM | UPEC | SORBONNE-UNIVERSITE

Citation

Romain Mathieu, Géraldine Pignot, Alexandre Ingles, Maxime Crépel, Pierre Bigot, et al.. Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features. Urologic Oncology: Seminars and Original Investigations, Elsevier, 2015, 33 (8), pp.339.e9-339.e15. ⟨10.1016/j.urolonc.2015.05.014⟩. ⟨hal-01260654⟩

Export

BibTeX TEI DC DCterms EndNote

Share

Metrics

Record views

388